1 – 10 of 285
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC
- Contribution to journal › Article
- 2025
-
Mark
Effect of inaccurate b-values from imaging gradients on intravoxel incoherent motion
- Contribution to journal › Article
-
Mark
Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy
- Contribution to journal › Article
-
Mark
Investigating the therapeutic potential of FLASH radiotherapy – a treatment planning study
- Contribution to journal › Article
-
Mark
Prostate-specific antigen bounce after prostate ultra-hypofractionation: associations with 5-year outcomes in the phase 3 trial HYPO-RT-PC
- Contribution to journal › Published meeting abstract
-
Mark
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation : Final overall survival results from the OPINION trial
- Contribution to journal › Article
-
Mark
Twenty Years of the Paediatric Radiation Oncology Society
- Contribution to journal › Article
-
Mark
Pre-operative sarcopenia as reflected by computed tomography predicts post-operative complications in patients undergoing total laryngectomy for head and neck cancer : a systematic review and meta-analysis
- Contribution to journal › Article
-
Mark
Primary treatment and survival in malignant ovarian germ cell tumors : A nationwide population-based Swedish Gynecologic Cancer Group (SweGCG) study
- Contribution to journal › Article
-
Mark
High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC : Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial
- Contribution to journal › Article
